LPCN ▼ -4.8% - Lipocine Inc. $LPCN LPCN - Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Lipocine announced the initiation of its BLOOM Phase 3 study evaluating LPCN 1154 for postpartum depression treatment. The stock declined 4.8% despite the clinical trial announcement, suggesting investors may have had concerns about trial design, competitive landscape, or other factors not reflected in the headline alone. 14-SEP-2026 08:04 AM ET